Any more recent information on the harms of kratom?

Defense of Kratom has recently become a more common and more heated topic.

I find that odd, as I’m not sure what defending or criticizing a molecule means.

That is to say, in the kind of chemistry class called “qualitative analysis” we learn the properties of a molecule. And for impacts of a molecule on humans, in physiological psychology and psychopharmacology, we learn the simple action of a molecule.

These kinds of facts lead to forming a list of what could be called “advantages” and “disadvantages” in their intent vs. their impact – when consumed by a human for whatever reason – under various circumstances in a person’s life.

Given what seems to be such a hot-button defense of kratom currently, I thought I would do a simple “Harms of Use” style search of the academic/research literature in the most recent 5 years and post some key findings or statements. And I also thought I’d check NIDA for their latest fact sheet on Kratom.

I’ll put some of that material here in this post for ease of the reader. And I’ll do so in reverse chronological order.

For those not particularly interested in those kinds of facts, I encourage skipping down to the Conclusion and “So what?” sections at the ending of this post.


First, let’s look at some information from NIDA in their March 11, 2026 update on Kratom.

Some people who use kratom have reported mild side effects, such as nausea, constipation, dizziness and drowsiness. In case reports, clinicians report seeing patients with a wide range of rare but serious adverse effects associated with kratom exposure—including mental and neurological symptoms (confusion, tremors and seizures), heart and lung problems (high blood pressure and slow breathing), gastrointestinal problems (nausea and vomiting) and liver problems. A very small number of deaths have been linked to kratom products, and nearly all cases involved other drugs or contaminants

Because kratom research is relatively new compared to more widely used drugs, there is little evidence to determine how kratom use may affect someone over time.

Researchers have not proven kratom to be safe or effective for any medical purpose, though kratom has been used in traditional medicine.


Next, I’ll provide a few statements from a 2025 paper in Current Psychiatry Reports.

Kratom products have been available in the US for over a decade. Initially, these products were almost entirely made from kratom leaf material and formulated in powders, capsules, or tablets. Recently, more diverse kratom products and derivatives have been marketed and sold, including extracts, concentrates, and isolates.

Recently, several concentrated or semi-synthetic products have entered the market that are advertised as kratom, but which pharmacologically bear little similarity to traditional kratom. Although the alkaloid content naturally ranges from 2 to 5% in native leaf material, it can be up to 60% in concentrated extracts.


A 2022 paper titled, “Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature” published in The American Journal of Drug and Alcohol Abuse, states:

Kratom (Mitragyna speciosa Korth.) products are increasingly endorsed for self-management of multiple ailments, including as opioid substitution. The FDA has expressed that there is no evidence to indicate that this botanical is safe or effective for any medical use.

With no reported controlled human clinical trials, in the light of rising concerns surrounding kratom’s liabilities, there is insufficient evidence to allow any conclusions to be drawn. Case reports and observational studies carry significant bias toward harm and efficacy, respectively.


A free, full-text article from 2021 in WIREs Forensic Science states:

…recreational use and non-medically supervised use of the drug in the West has escalated considerably over the past decade.

Viewed as a legal, ‘safe’ or ‘natural’ alternative to opioids, kratom has gained widespread use for the non-medically supervised treatment of chronic pain, anxiety, and opioid withdrawal.

In this review, the origins, pharmacology, uses, effects, and analysis of the drug are reviewed from a toxicological standpoint.

Personally, I found it interesting that this paper outlines: CYP3A4 as the primary cytochrome P-450 enzyme responsible for its metabolism (which obviously raises the question of drug interactions with various foods, medications, over-the-counter products, and street drugs involving 3A4).

I also found it interesting that the half-life of mitragynine in rats following oral administration is between 3.9 and 9.4 hours. Why did I find that interesting? That’s a fairly wide range in half-life from a clinical-applied perspective.

Meanwhile, the same article states the half-life in humans following oral administration of kratom tea is 23 +/- 16 hours. Yes, that’s 23hrs plus/minus 16 hrs. For humans, I find that even more interesting. My clinical-applied reflex is to say something like, “Don’t use it, if only because of such a wide half-life.”

It’s a detailed and super interesting paper. I’ll be reading it in its entirety, most likely.


Rineshkumar Ghirao: Unsplash

Conclusion

Regular readers of Recovery Review might know that given my clinical role, I’m generally more interested in the harm I might cause (which should be “none”) than the harm I merely reduce. Thus, my “Harms of Use: A List of References” approach.

And they might also know I’m interested in answering the question: “What if a drug could be a replacement for heroin and was low-cost, widely available, pharmaceutically pure, culturally accepted, and not tainted with high-potency but pure opioid additives, like fentanyl?”

My answer is found in my post that looks at the fourth most commonly used psychoactive substance on the planet: betel nut.

It turns out that betel nut meets those criteria and is also a public health nightmare. If you didn’t grow up in Southeast Asia and are unfamiliar with betel nut, you owe it to yourself to read that post.


“So What?”

Good point.

Yes, it’s interesting to me that I didn’t see anything in any of those papers I’ve cited about kratom being “recovery-safe” or not for people with severe, complex, chronic SUDs. Or about it being prognostically concerning or not for those with less severe, less complex, and less chronic SUDs.

I guess I’ll have to do a specific search for papers like that.

Leave a Reply